{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:24:53Z","timestamp":1791833093645,"version":"4.3.4"},"reference-count":22,"publisher":"Baishideng Publishing Group Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Gastrointest Surg"],"abstract":"<jats:p>BACKGROUND<\/jats:p>\n          <jats:p>Advanced pancreatic cancer is resistant to chemotherapeutic drugs, resulting in limited treatment efficacy and poor prognosis. Combined administration of the chemotherapeutic gemcitabine and erlotinib is considered a potential first-line treatment for advanced pancreatic cancer. However, their comparative benefits and potential risks remain unclear.<\/jats:p>\n          <jats:p>AIM<\/jats:p>\n          <jats:p>To assess the clinical efficacy and safety of erlotinib combined with other chemotherapy regimens for the treatment of advanced pancreatic cancer.<\/jats:p>\n          <jats:p>METHODS<\/jats:p>\n          <jats:p>Literature on the clinical efficacy and safety of erlotinib combined with chemotherapy for advanced pancreatic cancer was retrieved through an online search. The retrieved literature was subjected to a methodological qualitative assessment and was analyzed using the RevMan 5.3 software. Ten randomized controlled trials involving 2444 patients with advanced pancreatic cancer were included in the meta-analysis.<\/jats:p>\n          <jats:p>RESULTS<\/jats:p>\n          <jats:p>Compared with chemotherapeutic treatment, erlotinib combined with chemotherapy significantly prolonged the progression-free survival time of pancreatic cancer patients [hazard ratio (HR) = 0.78, 95%CI: 0.66\u20130.92, P  = 0.003]. Meanwhile, the overall survival (HR= 0.99, 95%CI: 0.72\u20131.37, and P  = 0.95) and disease control rate (OR = 0.93, 95%CI: 0.45\u20130.91, P  = 0.84) were not significantly favorable. In terms of safety, the erlotinib and chemotherapy combination was associated with a significantly higher risk of diarrhea (OR = 3.59, 95%CI: 1.63\u20137.90, P  &lt; 0.05) and rash (OR = 3.63, 95%CI: 1.64\u20138.01, P  &lt; 0.05) compared with single-agent chemotherapy. Moreover, the risk of vomiting (OR = 1.27, 95%CI: 0.62\u20132.59, P  = 0.51), regurgitation\/anorexia (OR = 1.61, 95%CI: 0.25\u201310.31, P  = 0.62), and infection (OR = 0.72, 95%CI: 0.28-1.87, P  = 0.50) were not significant in either group.<\/jats:p>\n          <jats:p>CONCLUSION<\/jats:p>\n          <jats:p>Compared with a single chemotherapeutic modality, erlotinib combined with gemcitabine can prolong progression-free survival in pancreatic cancer, but does not improve survival benefit or disease control rate, and can increase the risk of diarrhea and rash.<\/jats:p>","DOI":"10.4240\/wjgs.v16.i3.921","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T12:44:12Z","timestamp":1711025052000},"page":"921-931","source":"Crossref","is-referenced-by-count":3,"title":["Clinical efficacy and safety of erlotinib combined with chemotherapy in the treatment of advanced pancreatic cancer: A meta-analysis"],"prefix":"10.4240","volume":"16","author":[{"given":"Xiao-Yan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Nian","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.11.081"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00141-0"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-018-0685-y"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1042\/BST20191055"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27092981"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.11.006"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3310\/hta19470"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu435.87"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4216"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.07.9525"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4324"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-012-1234-y"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000633"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6463"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2013.158"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0878"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.4_suppl.329"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0005-x"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002234"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.6428"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3547"}],"container-title":["World Journal of Gastrointestinal Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1948-9366\/full\/v16\/i3\/921.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/1948-9366\/full\/v16\/i3\/921.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T12:46:02Z","timestamp":1711025162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1948-9366\/full\/v16\/i3\/921.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":22,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.4240\/wjgs.v16.i3.921","relation":{},"ISSN":["1948-9366"],"issn-type":[{"value":"1948-9366","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,27]]}}}